|
Generic:
|
| Sitagliptin, Metformin |
| Therapeutic Class: |
|
DPP-IV Inh & Biguanide Comb
|
|
Composition:
|
| GlyziaMet contains 50 mg sitagliptin and either 500 mg metformin hydrochloride extended-release (50 mg/500 mg) or 1000 mg metformin hydrochloride extended-release (50 mg/1000 mg). |
|
|
Description:
|
|
GlyziaMet tablets contain two oral antidiabetic medications used in the management of type 2 diabetes: Sitagliptin and Metformin hydrochloride.
|
|
|
Indications:
|
| GlyziaMet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate. |
| Dosage: |
| The dose of GlyziaMet should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin. Initial combination therapy or maintenance of combination therapy should be individualized and left to the discretion of the healthcare provider. In patients not currently treated with metformin, the recommended total daily starting dose of GlyziaMet is 100 mg sitagliptin and 1000 mg metformin hydrochloride (HCl).
Presentation:
GlyziaMet (Sitagliptin/Metformin) Tab 50/500 mg and 50/1000 mg is available in pack of 14’s. |
|
